Gene test to predict early treatment failure in follicular lymphoma
Assay Development and Prognostic Model for Predicting Early Clinical Failure in Follicular Lymphoma
['FUNDING_OTHER'] · UNIVERSITY OF ARIZONA · NIH-11195009
A lab test that reads genes in lymphoma biopsy tissue to spot people with follicular lymphoma who are likely to have their disease return within two years after standard immunochemotherapy.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF ARIZONA (nih funded) |
| Locations | 1 site (TUCSON, UNITED STATES) |
| Trial ID | NIH-11195009 on ClinicalTrials.gov |
What this research studies
You would be asked to let researchers use routine biopsy tissue (formalin-fixed, paraffin-embedded) from your lymphoma to run a gene-expression test called FL24Cx on the NanoString nCounter platform. In the first phase they will refine and standardize the assay for clinical-grade use, and in the second phase they will validate how well the test predicts early clinical failure (failing to remain event-free at 24 months after treatment). The team will compare test results against known outcomes from treated patients, using archived and prospectively collected samples to measure accuracy. The goal is a reliable test that can be run on usual pathology specimens so results could be used in real clinical care.
Who could benefit from this research
Good fit: Ideal candidates are people with newly diagnosed or recently treated follicular lymphoma who have available tumor biopsy tissue (FFPET) from diagnosis or treatment.
Not a fit: Patients without available biopsy tissue, those with non-follicular lymphomas, or people already more than two years past treatment are unlikely to benefit directly from this project.
Why it matters
Potential benefit: If successful, the test could help doctors identify high-risk follicular lymphoma patients at diagnosis so treatment can be tailored earlier.
How similar studies have performed: The team has an internally validated gene-expression signature and similar NanoString-based prognostic tests in other cancers have shown promise but require external validation.
Where this research is happening
TUCSON, UNITED STATES
- UNIVERSITY OF ARIZONA — TUCSON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: RIMSZA, LISA — UNIVERSITY OF ARIZONA
- Study coordinator: RIMSZA, LISA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Brill-Symmers Disease